XBiotech Inc.
XBITNasdaq
$2.27
↓ -0.9%Jul 17 close · end-of-day
Price
1Y↓ -23.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$40.2M
Free Cash Flow (TTM)
-$42.4M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-29.8%
ROIC
-195.5%
Debt / Equity
—
Net Cash
$115.5M
Return 1Y
-24.3%
Company profile
XBiotech Inc. discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis.
- CEO
- John Simard
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 100
- Headquarters
- Texas
- Website
- xbiotech.com
Earnings
XBIT Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $44.0M | $18.4M | $4.0M | $0.00 | — | — |
| Gross profit | $9.4M | $12.6M | $3.4M | $0.00 | — | — |
| Operating income | -$18.3M | -$25.1M | -$34.5M | -$37.5M | -$42.5M | -$55.7M |
| Net income | -$11.2M | -$17.4M | -$32.9M | -$24.6M | -$38.5M | -$45.5M |
| Diluted EPS | -$0.36 | -$0.58 | -$1.08 | -$0.81 | -$1.26 | -$1.49 |
| Operating cash flow | -$65.1M | $69.4M | -$14.8M | -$18.7M | -$31.0M | -$39.9M |
| Free cash flow | -$68.9M | $65.9M | -$15.4M | -$19.1M | -$32.3M | -$40.2M |
| Gross margin | 21.5% | 68.4% | 83.8% | — | — | — |
| Operating margin | -41.5% | -136.4% | -860.1% | — | — | — |
| Net margin | -25.5% | -94.7% | -820.4% | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$15.0M | -$7.9M | -$8.7M | -$13.6M | -$6.3M | -$6.0M | -$29.8M | -$6.3M |
| Net income | -$13.0M | -$5.0M | -$10.5M | -$10.9M | -$1.8M | -$6.0M | -$26.9M | -$5.5M |
| Diluted EPS | — | — | — | — | — | — | — | — |
| Operating cash flow | -$11.4M | -$5.8M | -$6.5M | -$6.7M | -$6.0M | -$4.3M | -$23.0M | -$9.0M |
| Free cash flow | -$12.0M | -$6.2M | -$6.6M | -$6.8M | -$6.0M | -$4.4M | -$23.0M | -$9.0M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Nov 12, 2025
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.